Skip to main content

Table 2 Univariate and multivariate analysis for time to first therapy (TFT) in this series

From: MicroRNA-223 is a novel negative regulator of HSP90B1 in CLL

  Univariate analysis Multivariate analysis
Characteristics Events Total Median LCI UCI P HR LCI UCI P
HSP9081 expression    
Normal 12 39 104.0 - - - - - - -
High 28 39 17.0 5.0 28.9 0.024 2.7 1.18 6.46 0.026
IGVH identity  
<98% 15 60 104.0 11.3 196.7 - - - - -
≥98% 39 57 14.0 6.8 21.2 <0.001 2.34 1.03 5.35 0.043
Lymphocyte  
<30000 35 90 53.0 35.1 70.8 - - - - -
≥30000 25 37 8.0 0.0 17.5 <0.001 4.2 1.75 10.05 0.001
Cytogenetics
Good prognosis 28 82 57.0 38.3 75.7 - - - - -
Poor prognosis 16 21 9.0 1.7 16.2 <0.001 1.65 1.907 2.54 0.023
Age (years)
≥65 29 71 42.0 18.3 65.7 - - - - -
<65 29 53 24.0 6.6 41.4 0.04 0.37 0.17 0.83 0.015
B symptoms  
No 42 194 49.0 34.3 63.7 - - - - -
Yes 15 18 1.0 0.0 2.1 <0..001 0.17 0.06 0.53 0.002
  1. IGVH: immunogllobulin heavy variable gene; LCI: 95% lower confidence interval; UCI: 95% upper confidence interval; HR: Hazard ratio.
  2. Time to first theraphy (TFT) was defined as the interval between diagnosis and the treatment.